ObjectiveTo investigate the clinical effect of azithromycin combined with gamma globulin in the treatment of children with mycoplasma pneumoniae pneumonia (MMP) and its influences on immune function. MethodsA total of 90 children with MMP admitted to our hospital from January 2018 to April 2020 were selected and divided into combined group and single drug group by the random number method, with 45 cases in each group. The children in the single drug group were treated with azithromycin, whereas the children in the combined group were treated with azithromycin combined with gamma globulin, for a 5-day treatment course. The clinical efficacy, improvement time of symptoms and signs, improvement of inflammation and immune function, and occurrence of adverse reactions were compared between the two groups. ResultsAfter 5 days of treatment, the total effective rate of the combined group (95.6%) was significantly higher than that of the single drug group (80.0%), with a statistically significant difference (P＜0.05). The children in the combined group obtained shorter time of cough relief, fever relief, pulmonary imaging improvement, and lung rales disappear as compared with the single drug group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in the levels of C-reactive protein (CRP), immunoglobulin (Ig) A, IgM and IgG between the two groups (P＞0.05). After 5 days of treatment, the combined group yielded a lower level of CRP, whereas higher levels of IgA, IgM, and IgG as compared to the single drug group (P＜0.05). During the treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionAzithromycin combined with gamma globulin has prominent clinical efficacy for the treatment of children with MPP. It can effectively alleviate inflammatory responses of children, improve immune function, and promote recovery of children.

无